About Shanghai Yizhong Pharmaceutical Company

The company was founded in September 2009 as a company listed on the Science and Technology Innovation Board, stock code: 688091. Shanghai Yizhong currently has a highly qualified R&D team with professional backgrounds in pharmaceutical preparations, drug analysis, polymer material synthesis, etc., and has advanced production equipment and inspection instruments that meet GMP standards. The company is a pioneer enterprise in innovative drug research and development in China. It has nanotechnology and the core key technology for the preparation of pharmaceutical polymer excipients. It is uniquely innovative in nano-drug delivery systems. It can use pharmaceutical excipients with different molecular weights for clinical application to improve dosage forms through this technology, greatly improving their safety and efficacy, and giving them new value and vitality. The company is committed to the development of innovative anti-tumor drugs and related products. It is a high-tech pharmaceutical enterprise integrating R&D, production and sales. The company's core product “injectable paclitaxel polymer micelle”. Corporate honors: It has successively won many honors such as the free funding project of the National Science and Technology SME Innovation Fund and the Shanghai Science and Technology Commission's scientific and technological achievement transformation and industrialization project. Clinical studies on non-small cell lung cancer have shown that the objective remission rate (ORR) and progression-free survival (PFS) of micellar tumor treatment with paclitaxel have obvious clinical advantages over other paclitaxel dosage forms that have already been marketed.